Cargando…

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Migliori, Giovanni Battista, Pontali, Emanuele, Sotgiu, Giovanni, Centis, Rosella, D’Ambrosio, Lia, Tiberi, Simon, Tadolini, Marina, Esposito, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343876/ https://www.ncbi.nlm.nih.gov/pubmed/28178199 http://dx.doi.org/10.3390/ijms18020341

Ejemplares similares

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Sotgiu, Giovanni, et al.
Publicado: (2016)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

New anti-tuberculosis drugs and regimens: 2015 update
por: D'Ambrosio, Lia, et al.
Publicado: (2015)

Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature
por: Esposito, Susanna, et al.
Publicado: (2016)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Recent developments in the diagnosis and management of tuberculosis
por: Sulis, Giorgia, et al.
Publicado: (2016)

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium
por: D’Ambrosio, Lia, et al.
Publicado: (2017)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany
por: Eker, Barbara, et al.
Publicado: (2008)

COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom
por: García-García, José-María, et al.
Publicado: (2022)

Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis
por: Silva, Denise Rossato, et al.
Publicado: (2018)

The battle against colistin-resistant E. coli and the need for a one health approach
por: Danaei, Bardia, et al.
Publicado: (2023)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID Lungs
por: Pontali, Emanuele, et al.
Publicado: (2022)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating
por: Sotgiu, Giovanni, et al.
Publicado: (2021)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!
por: Tiberi, Simon, et al.
Publicado: (2018)

International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis
por: Migliori, Giovanni Battista, et al.
Publicado: (2019)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

The challenge of managing extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases
por: Arbex, Marcos Abdo, et al.
Publicado: (2015)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study
por: Nalunjogi, Joanitah, et al.
Publicado: (2023)

Tuberculosis in the time of COVID-19: quality of life and digital innovation
por: Visca, Dina, et al.
Publicado: (2020)

The definition of tuberculosis infection based on the spectrum of tuberculosis disease
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hcgd0nh8sg33e6j1h73qkg63hr